Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-2 study of MORF-057 in moderately to severely active ulcerative colitis
2022-500953-17-00Phase 2Completed
- Sponsor
- Morphic Therapeutic
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of LY4268989 in autoimmune colitis (4 arms), sponsored by Morphic Therapeutic. Primary endpoint: Clinical remission at Week 12 by modified Mayo Clinic Score. Started Mar 2023; status: completed.
02
Drugs
LY4268989
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-500953-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500953-17-00.